This study has examined the cellular and humoral responses underlying the rejection ofrat renal allografts bearing an isolated RTIAa class I MHC disparity. RTIAa disparate kidneys were rejected promptly by high responder RTlu but not by low responder RT1°recipients (median survival time 10 d and >100 d, respectively) . The magnitude and phenotype of the cellular infiltrate were similar in rejecting and nonrejecting RTIAa disparate kidneys . Paradoxically, graft infiltrating cells and spleen cells from RT1°recipients showed minimal ability to lyse donor strain lymphoblasts in vitro, whereas effector cells from RT1°recipients showed modest levels of cytotoxicity. Injection of RTlu rats with MRC OX8 mAb was highly effective at selectively depleting CD8+ cells from graft recipients but had no effect in prolonging the survival of RT1Aa disparate grafts despite the complete absence of CD8+ cells from the graft infiltrate, which included numerous CD4+ T cells and macrophages. RT1°, but not RT1°, recipients mounted a strong alloantibody response against RT1Aa disparate kidneys . Immune serum obtained from RTlu recipients that had rejected a RT1A°disparate graft was able, when injected into cyclosporin-treated RTlu recipients, to restore their ability to reject a RT1Aa, but not a thirdparty RT1°, kidney. These results suggest that CD8+ cells in general and CD8+ cytotoxic effector cells in particular are unnecessary for the rapid rejection of RTIA2 class I disparate kidney grafts by high responder RTlu recipients . By implication, CD4+ T cells alone are sufficient to cause prompt rejection ofsuch grafts and they may do so by providing T cell help for the generation of alloantibody.
Summary
This study has examined the cellular and humoral responses underlying the rejection ofrat renal allografts bearing an isolated RTIAa class I MHC disparity. RTIAa disparate kidneys were rejected promptly by high responder RTlu but not by low responder RT1°recipients (median survival time 10 d and >100 d, respectively) . The magnitude and phenotype of the cellular infiltrate were similar in rejecting and nonrejecting RTIAa disparate kidneys . Paradoxically, graft infiltrating cells and spleen cells from RT1°recipients showed minimal ability to lyse donor strain lymphoblasts in vitro, whereas effector cells from RT1°recipients showed modest levels of cytotoxicity. Injection of RTlu rats with MRC OX8 mAb was highly effective at selectively depleting CD8+ cells from graft recipients but had no effect in prolonging the survival of RT1Aa disparate grafts despite the complete absence of CD8+ cells from the graft infiltrate, which included numerous CD4+ T cells and macrophages. RT1°, but not RT1°, recipients mounted a strong alloantibody response against RT1Aa disparate kidneys . Immune serum obtained from RTlu recipients that had rejected a RT1A°disparate graft was able, when injected into cyclosporin-treated RTlu recipients, to restore their ability to reject a RT1Aa, but not a thirdparty RT1°, kidney. These results suggest that CD8+ cells in general and CD8+ cytotoxic effector cells in particular are unnecessary for the rapid rejection of RTIA2 class I disparate kidney grafts by high responder RTlu recipients . By implication, CD4+ T cells alone are sufficient to cause prompt rejection ofsuch grafts and they may do so by providing T cell help for the generation of alloantibody. S tudies of the cellular response to allografts expressing isolated class I or class II MHC disparities have contributed substantially to current understanding of the relative roles of CD4+ and CD8+ T cells in graft rejection (1) (2) (3) (4) (5) (6) (7) . Adoptive transfer experiments in T cell-depleted mice bearing mutant class I or class II disparate skin grafts have shown that purified Lyt-2+ (CD8+) but not L3T4+ (CD4+) cells initiate rejection of class I disparate skin grafts, whereas L3T4+ but not Lyt-2+ cells initiate rejection of class II disparate grafts (1) (2) (3) . The contribution of CD8+ T cells to the rejection of mouse skin grafts bearing mutant or allelic class I disparities has been confirmed by the demonstration that treatment with anti-Lyt-2 to selectively deplete CD8+ T cells prolongs graft survival (4, 6) . Although selective depletion of CD4+ T cells using anti-L3T4 does not prolong the survival of skin grafts bearing an isolated class I disparity, there is evidence that in some mouse strain combinations, CD4+ T cells may also participate in the rejection of such grafts (6) .
Most reports on the cellular effector response to isolated class I disparate tissue relate to skin graft models in the mouse.
We chose to examine the immunological response to rat kidney allografts differing at an isolated class I MHC antigen because it is likely that there are important differences in the nature of the rejection response between indirectly vascularized skin and directly vascularized organ grafts. In addition, the rat renal allograft model enabled us to make a detailed analysis of the phenotype and in vitro cytotoxic activity of cells infiltrating the grafts . The rejection of allografts bearing the genetically isolated RT1Aa class I antigen is under strict Ir gene control; the PVG RTl°and PVG RTlu strains are low and high responders, respectively (8, 9) . Using the appropriate intra-MHC recombinant rat strains as kidney donors we were therefore able to compare the cellular and humoral response with rejecting and nonrejecting class I RT1Aa kidney grafts.
Materials and Methods
Animals. The PVG congenic and recombinant rat strains used are shown in Table 1 together with their MHC haplotypes. Animals Kidney Transplantation . Kidneys were transplanted into the left orthotopic site with end-to-end anastomosis of the renal artery, renal vein, and ureter (13) . The procedure was performed under chloral hydrate anesthesia and ischemic times were -25 min. For graft survival studies, the recipient's right kidney was excised 7 d after transplantation so that the continued survival of the transplanted animal was dependent on the function of the renal graft. Graft function was also monitored by performing sequential serum urea and creatinine measurements.
Cprlosporin A Treatment . Rats received 15 mg/kg of cyclosporin (a gift from Sandoz Pharmaceuticals), dissolved in olive oil, via a gastric tube on the day of transplantation, and then daily for the next 13 d.
Antibodies BALB/c)F, mice (Harlan Olac Ltd.) to produce ascites. The immunoglobulin content of ascites was quantified using anti-mouse IgGl immunodiffusion plates and known mouse Ig standards (Serotec Ltd.) . Antibodies were diluted in PBS to 2 mg/ml and stored at -20°C. They were administered intraperitoneally to recipient rats according to the following schedule : 3 mg on day -1, 2 mg on day 0 (day of transplant), and 1 mg on days 3, 6, and9.
Cell Preparation and Fluorescence Analysis. Single cell suspensions of lymph nodes and spleen were prepared as described previously (21) . PBL were separated by centrifugation of heparinized whole blood over 75% iso-osmolar Percoll (Sigma Ltd., Poole, UK). For
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Rejection of RT1AA Disparate Morphometric Analysis of -Cellular Infiltrate. The area of each immunoperoxidase-labeled tissue section infiltrated by leukocytes of a particular phenotype was determined by morphometric analysis using the point-counting technique as previously described (23) . Sections were examined at a magnification of x 400 in the presence of a microscope eyepiece graticule bearing a squared grid with 745 intersections . For each of 10 adjacent high power fields, the number of positively stained cells superimposed by an intersection was counted and the percentage area of each section occupied by cells of a particular phenotype was calculated as : 100 x [(number of positive cells under grid intersections)/ (total number of grid intersections)]-Harvesting of Graft Infiltrating Cells. Graft infiltrating cells (GIC)' were harvested from kidney allografts by a nonenzymatic technique as described previously (21). In brief, the freshly excised kidney allografts were finely diced, passed through a fine stainless steel mesh and the mononuclear cells separated from the resulting cell suspension by Percoll density gradient centrifugation .
Cell-mediated Cytotoxicity Assays. GIC and spleen cells from transplanted recipients were tested for alloantigen-specific cytotoxicity and nonspecific cytotoxicity using a standard 6-h "Cr-release assay essentially as described elsewhere (24) . Alloantigen-specific cytotoxicity was assessed using "Cr-labeled kidney donor strain and third-party Con A-transformed splenic blasts as targets. The mouse lymphoma line YAC-1 (which is susceptible to NK cell-mediated lysis) was also used as a target . Specific "Cr release was calculated by the formula: percent specific release = 100 x [(experimental release -spontaneous release) /(maximum releasespontaneous release)] . Data shown are the means of triplicate determinations (spontaneous release <25% of maximum release in all experiments) .
Radioimmunoassay for Anti-RTIA°Antibodies . Antibodies against RTIA' class I antigens were detected by a two-stage binding assay usingdonor strain erythrocytes and radiolabeled sheep anti-rat Ig (25) . Serial dilutions of test sera in DAB/2% FCS were added, in duplicate 50-Al aliquots, to the wells of 96-well U-bottomed microtiter plates (Flow Laboratories, Rickmansworth, UK) that had been pretreated with 2% BSA/DAB (to prevent nonspecific binding of Ig). To each well, 50 Al of a 2% suspension of washed rat erythrocytes was added and the plates were incubated for 1 h at room temperature and then washed four times in DAB/FCS. Next, 100 ul '211-conjugated F(aV)z sheep antibodies against rat Ig (Amersham International, Amersham, UK) was added (ensuring at least 50,000 cpm/well) and the plates were incubated for a further 1 h. The erythrocytes were then washed a further four times, transferred to tubes, and the cell bound radioactivity was counted. Lpmphocytotcaric Antibody Deteminations Test sera were incubated with 5'Cr-labeled Con A-transformed splenic blast targets in the presence of guinea pig complement (Sera-Lab, Sussex, UK) or fresh rat serum in a cytotoxicity assay as follows. Serial dilutions of test sera in RPMI/10 mM Hepes/5% FCS were prepared in 96-well U-bottomed microtiter plates in duplicate aliquots of 50 gl . "Crlabeled Con A-transformed splenic blasts at 106 per ml in RPMI/ Hepes/FCS were added to each well, and incubated at 37°C for 30 min. 100 Al guinea pig complement (Sera-Lab) or fresh rat serum, appropriately diluted, were added and incubated for 1 h at 37°C . Plates were then centrifuged briefly, and 100-Id aliquots of supernatant were transferred to tubes for counting released "Cr. Specific "Cr release was calculated by the formula: Percent specific release = 100 x [(experimental release -spontaneous release)/(maximum release -spontaneous release)].
Results
Rejection of Renal Allografts Bearing an Isolated RnA' Class I MHC Disparity. Rejection of RTlA' incompatible skin and organ grafts is under strict MHC-linked immune response gene control (8, 26, 27) . The PVG RT1" strain is a high responder to class I RTIA' incompatible grafts from the PVG R8 donor whereas the PVG RT1°strain is a low responder to RTIA' incompatible grafts from PVG Rl animals. This was confirmed here for renal allografts (Table 2 ) . R8 kidneys were rapidly rejected by RTl°recipients, which died shortly after contralateral nephrectomy (MST 10 d) with markedly raised serum urea and creatinine levels. Grafts excised 5 d after transplantation already showed histological features of severe rejection, with widespread vascular damage and associated intravascular fibrin and platelet deposition. Focal tubular necrosis and ischemia of glomeruli were present and there was an interstitial mononuclear cell infiltrate . By day 7, extensive interstitial hemorrhage was apparent and grafts had frequently undergone complete infarction. In contrast, R1 
1 r8 u 16 ± 10 (100%) 6 ± 1 (38%) 2 ± 1 (13%) 10 ± 6 (63%) 2 rl c 18 ± 1 (100%) 7 ± 2 (39%) 6 ± 2 (33%) 9 ± 1 (50%) 3 a c 52 ± 12 (100%) 16 ± 11 (31%) 9 ± 6 (17%) 23 ± 8 (44%) 4 c c 4 ± 1 <1 3 ± 1 <1 kidneys survived indefinitely in RT1c recipients (MST >100 d) and serum urea and creatinine levels remained normal throughout . Rl grafts showed mononuclear cell infiltration but no evidence of renal parenchymal damage. The influence of Ir gene control on renal allograft survival was not apparent when an isolated A' class I disparity was replaced by a full haplotype RT1a MHC disparity since low responder RT1c animals rapidly rejected RT1' kidneys (MST 10 d).
Magnitude and Phenotype of Cellular Infiltrate in RTIAa Disparate Grafts. The demonstration that class I RT1Aa incompatible kidneys were rapidly rejected by RT1n recipients but not by RT1°recipients led us to compare the intragraft cellular responses. Our first approach was to assess the magnitude and phenotype of the cellular infiltrate within the grafts. Cryostat sections ofkidney allografts were labeled with a range of mouse anti-rat mAbs by an indirect immunoperoxidase technique and infiltrates assessed by morphometric analysis (Table 3 ). Both rejecting R8 grafts in RTl°recipients and nonrejecting R1 grafts in RT1c recipients showed a diffuse interstitial mononuclear cell infiltrate with perivascular mononuclear cell aggregates . The magnitude of cellular infiltration (determined by OXl) was similar in rejecting and nonrejecting grafts . The infiltrate in class I disparate grafts was fourfold greater than that observed in grafts between syngeneic animals, but substantially less than that found in rejecting grafts bearing a full haplotype RT1a disparity. The phenotype of the cellular infiltrate in rejecting and nonrejecting RT1A' disparate grafts was similar. CD8+ cells formed a large component of the total infiltrate but the predominant cell type was the macrophage (ED1+). CD4+ and CD8+ cells were distributed homogeneously within the infiltrate and there was no preferential localization of either phenotype to specific areas of the graft.
Cytotoxic Repertoire ofGIC and Splenocytes in Recipients with RTIAa Disparate Grafts. Butcher and Howard showed that high responder RTl" rats bearing RT1Aa incompatible skin grafts develop rytotoxic T cells in the draining lymph nodes and that generation of such cells is impaired in low responder RT1c rats (8) . We predicted, therefore, that GIC from rejecting RT1Aa disparate kidneys in RTlu recipients would, when tested in vitro, demonstrate higher levels of specific anti-donor rytotoxic activity than cells obtained from nonrejecting RT1A°grafts in RT1c recipients, thereby reflecting a role for cytotoxic T cells in the rejection response of these class I disparate grafts. To test this, the rytotoxic activity of GIC and spleen cells from these animals was studied in 6-h 51 Cr-release assays. The results of representative experiments are shown in Fig. 1 . Unexpectedly, GIC obtained from rejecting RTlAa incompatible R8 kidneys in high responder RT1°recipients showed minimal ability to lyse Con A blasts of the kidney donor strain. Paradoxically, GIC from nonrejecting RT1A' disparate R1 grafts in low responder RT1c recipients often showed modest levels of cytotoxicity against donor strain lymphoblasts . However, this cytotoxicity was not entirely donor specific, since lysis of third-party Con A blasts was also apparent. As expected, full MHC disparate rejecting RT1a grafts in cytotoxic activity. This last result is important since it confirms that the specific cytotoxic activity ofGIC, when it is present, can be readily detected under the in vitro conditions used in these experiments . GIC from all grafts were able to lyse the NK-susceptible target YAC-1 but levels of cytotoxicity were lowest in rejecting RTlAa incompatible grafts . The cytotoxic activity ofspleen cells from the graft recipients was also tested and showed the same general pattern as that already described for GIC . As before, the most notable observation was the inability of effector cells, from RTl°r ecipients bearing a rejecting RT1Aa disparate R8 graft, to show significant levels of specific killing of donor lymphoblasts (donor specific lysis was <10% in all of 10 recipients tested) . Effect ofAnti-CD8 (MRC OX8) Antibody on Renal Allograft Rejection . The finding that class I incompatible R8 kidneys were rapidly rejected by high responder RT1°recipients but that the graft infiltrate, when tested in vitro, showed little ability to lyse donor strain target cells led us to question whether CD8 effector cells play an essential role in the rejection of RTIA' disparate grafts . We therefore specifically depleted CD8+ cells from RTlu rats, by in vivo treatment with the mAb MRC OX8, and then examined their ability to reject RTIA°kidneys. FACS analysis (Fig. 2) , together with immunohistology (results not shown), indicated that after MRC OX8 treatment was started, (according to the protocol described in Materials and Methods), CD8' cells were undetectable in the blood, lymph nodes, and spleen of RTlu rats for at least 14 d. This was not due to masking of the CD8 antigen by antibody coating since mouse Ig was not detectable on the surface of lymphoid cells . Loss of CD8+ cells was associated with a corresponding increase in the relative frequency of residual CD4+ T cells and MRC OX12+ B cells . Confirmation that MRC OX8 treatment caused depletion of CD8+ cells rather than modulation of the CD8 antigen was obtained by dual staining with R73 (which labels the TCR-ci//3) and either MRC OX8 or W3/25 (Fig. 3) . After in vivo treatment with MRC OX8, the CD8+ TCR ci/Q+ cell population was completely eliminated and all residual TCR-a/o+ cells coexpressed the CD4 antigen .
Although MRC OXS treatment depleted CD8+ cells from RT1°rats, it had no effect on their ability to reject RTIA' class I disparate renal allografts (Table 4) . Survival times for graft recipients given MRC OX8 were the same as those for recipients treated either with MRC OX21 (control mAb) or left untreated (MST 10 d in all groups) . Rejection in MRC OX8-treated recipients was accompanied by mononuclear cell infiltration of the graft together with a T cell-dependent anti-RTIA' cytotoxic alloantibody response (similar to that found in untreated recipients, results not shown) . The CD8+ infiltrate previously observed in rejecting RTIA' disparate grafts from untreated recipients was completely absent from rejecting grafts in MRC OX8-treated animals (Fig. 4, a and b) . Much o£the residual infiltrate comprised macrophages, as shown by labeling with EDl (Fig.  4 c) . There were also numerous T cells within the graft, as shown by expression of the TCR-ci/0 (Fig. 4 d) . Two-color FACS analysis of the harvested GIC confirmed that this cell population consisted exclusively of TCRci/a+ CD4+ T cells (results not shown) . Grafts. Ir gene control is known to have a strong influence not only on graft survival but also on the production of T-dependent anti-RTIA' alloantibody (9) . This influence was readily apparent in the present experiments . High responder RTlu recipients developed a strong anti-RTIA' antibody response to R8 kidney grafts as detected by a twostage binding assay using donor strain erythrocytes ' (Fig . 5) . In contrast, low responder RT1°recipients showed a minimal antibody response to class I incompatible Rl grafts. When the sera from grafted animals were assayed for cytotoxic antibody, RT1°recipients showed a progressively increasing anti-RTla antibody response detectable from day 3 after transplantation, whereas cytotoxic antibody in RT1°r ecipients was barely detectable on any day after transplantation (Fig. 6) . The cytotoxic antibody in RTlu recipients was specific for the RTIA' haplotype since it failed to lyse thirdparty RTl°target cells (results not shown) . The high levels of cytotoxic antibody in the serum of RT1°graft recipients were initially demonstrated by assays in which guinea pig serum was used as a source of complement . Fresh syngeneic RT1°rat serum was also effective as a complement source in these assays (Fig. 7) . In contrast, RT1c rat serum was not only ineffective but when mixed with RTlu serum appeared to inhibit its effectiveness as a complement source. The explanation for this unexpected difference is unclear and the phenomenon is currently being investigated further in our laboratory although one possibility is polymorphism in class III MHC gene products between the u and c MHC haplotypes.
Passive Transfer Experiments. To determine whether alloantibody played a role in the rejection of RTIA' disparate kidney grafts by RTlu recipients, a series of passive transfer experiments was undertaken (Table 5) . Immune serum for passive transfer was obtained from RTlu rats bearing a rejecting R8 kidney graft 5, 6, or 10 d after transplantation . Intravenous injection of immune serum into low responder RT1c recipients of R1 kidneys did not cause graft rejection (MST >50 d, no increase in serum urea or creatinine) . This result did not, however, exclude a role for cytotoxic alloantibody in the rejection of RTIA' disparate grafts by high responder RTlu recipients because, as already noted, RT1c rat serum (in contrast to RTlu serum) was not effective as a Recipient rats were treated in vivo with either MRC OX8 or MRC OX21 (control). mAbs were given intraperitoneally on days -1, 0, 3, 6, and 9 as described in Materials and Methods.
t Contralateral nephrectomy performed on day 7.
S Median survival time.
Rejection of RTIA°Disparate Rat Renal Allografts complement source for assaying the in vitro cytotoxicity of RTlu anti-RTIAa antibody. The ability of immune serum to cause renal allograft rejection in cyclosporin-treated UP recipients was therefore tested (Table 5) 
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R8 kidney grafts (MST > 50 days) and also abrogated their antibody response to these grafts (results not shown) . Injection of day 10 (but not day 5/6) immune serum restored the ability of cyclosporin treated RTlu rats to promptly reject a R8 kidney (MST 9 d) . This effect of immune serum was allospecific since injection of anti-RTlAa immune serum into cyclosporin-treated RTlu rats bearing a RT1°kidney did not cause graft rejection (MST > 50 d). The histopathological appearance of class I disparate grafts rejected in the presence of passively transferred immune serum was broadly similar to that of RT1Aa disparate grafts undergoing rejection in unmodified RTlu recipients . Damage to the graft vasculature was a major feature and neutrophil margination and infiltration (a characteristic feature of hyperacute rejection) was not apparent .
Discussion
Rat renal allografts bearing an isolated RTla class I disparity are rejected promptly by high responder UP but not Figure 7 . Complement-mediated cytotoxicity of s'Cr-labeled R8 Con A blasts by RTlu anti R8 immune serum (day 5 after transplant). The assay was performed in the presence of guinea pig complement (A), fresh RTlu (/), RTIc ("), or RTIu + RT1c (50:50 mixture) rat serum by low responder RT1°recipients . In this report we have shown that class I-restricted cytotoxic CD8+ effector cells are not necessary for the rejection of RTIAa disparate kidney grafts by UP recipients . This finding for class I disparate kidney grafts is ofinterest because most reports on the rejection of class I disparate skin or heart allografts in the rodent have emphasized the importance of the CD8+ T cell subset. Experiments in mice have shown that Lyt-2+ T cells play a major role in the rejection of class I disparate skin grafts, whereas L3T4+ cells may, depending on the strain combination, be unnecessary (1) (2) (3) (4) (5) (6) . Similarly, using a rat model, Lowry et al. (7) reported an absolute requirement for CD8+ cells in the rejection ofclass I disparate heart grafts by acutely irradiated rats, and in addition, suggested that this related to their role as cytotoxic effector cells. Moreover, congenitally athymic rats of low responder RTl°haplotype can only be induced to reject RTIA2 class I disparate skin grafts by the adoptive transfer ofboth CD4+ and CD8+ T cells (28) .
It has been recently shown that low responder RTl°and high responder RT1u rats have a similar frequency of antiRT1Aa T cytotoxic precursor cells and that the frequency of such cells increases in RTlu but not RT1c recipients of a class I RTIA' disparate cardiac allograft (29) . In the present study it is notable, therefore, that GIC harvested from rejecting RTlAa class I disparate kidney grafts showed minimal in vitro cytotoxicity towards donor strain lymphoblasts. Since in this and previous studies (23), we were able to demonstrate readily, the presence of substantial levels of specific cytotoxicity in rejecting grafts differing from their host at the entire (class I and class II) MHC locus the apparent absence of significant cytotoxicity in RTIAa class I disparate grafts led us to question whether class I-restricted cytotoxic effector cells played a necessary role in their rejection . According to the orthodox view, class I-restricted cytotoxic cells would bear the CD8+ phenotype (30) . We therefore tested ' Contralateral nephrectomy on day 7.
t Immune serum was obtained from RTlu recipients bearing rejecting R8 kidneys 5, 6, or 10 d after transplantation. After heat inactivation (56°C for 30 min) it was stored at -20°C and microfuged before use. 1 ml of immune serum (or normal RTlu serum) was given to graft recipients by i.v . injection on days 1, 2, 3, 4, and 5 after transplantation. S Cyclosporin was given daily (15 mg/kg) by gavage for 14 d after transplantation.
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Rejection of RTIA-Disparate Rat Renal Allografts the effect of depleting CD8+ cells from RTlu rats on their ability to reject an RTIA' disparate kidney. Injection of the mAb -MRC OX8 is highly effective at specifically depleting CD8+ cells from treated rats (31) (32) (33) . The loss of CD8+ cells is accompanied by a functional loss of specific alloreactive cytotoxicity and a marked reduction in NK cell activity (many rat NK cells are CD8+). In the present study, the MRC OX8 treatment schedule completely depleted CD8+ cells from the peripheral blood and lymphoid tissue of RTlu rats'for at least 2 wk after starting treatment. However, MRC OX8-treated RT1u rats showed no impairment in their ability to reject RT1A' renal allografts despite the complete absence of CD8 + GIC from the rejecting kidneys. Therefore, whereas CD8+ T cells may or may not contribute to the rejection of RT1A' disparate kidneys in unmodified RTlu recipients, their participation is not essential for the rejection of such grafts . Since rodents deficient in both CD4+ and CD8+ lymphocytes are unable to reject allografts, our results suggest that the CD4+ T cell subset is both able and sufficient to induce rejection ofclass I disparate renal allografts . Moreover, CD4+ cells appear to be essential for RT1u rats to reject RT1A' disparate kidneys promptly, since we have recently shown that depletion of CD4+ T cells by in vivo treatment with the mAbs MRC OX35 plus MRC OX38, given according to a previously described protocol (34), prevents rejection for at least several weeks (Porteous, C., E.M. Bolton and J.A. Bradley, manuscript in preparation).
Because CD4+ T cells are class II restricted, they would not be expected to recognize allo-class I MHC molecules directly, although exceptional CD4+ T cell clones have been described that are lytic towards class I MHC targets (35, 36) , and therefore direct recognition of class I molecules by CD4+ cells cannot be completely discounted. However, the contemporary view is that class I-restricted CD4+ T cells recognize allo-class I antigen that is processed and presented in the context of self class II MHC. With reference to the present experiments this implies that RTlu CD4+ T cells recognize A' antigen that has been processed, either by donor or host antigen-presenting cells, and is presented in the context of RTIB/Du class II MHC molecules.
The question arises as to the mechanism whereby CD4+ T cells activated in this way are able to mediate rejection of class I disparate kidney grafts. Numerous CD4+ T cells were identified within rejecting kidneys in MRC OX8-treated recipients, and in principal, they could mediate graft damage by recruiting and activating nonspecific cellular effectors in a classical DTH reaction . However, neither the immunohistological nor the functional comparison of GIC in rejecting and nonrejecting class I disparate kidneys supported this suggestion. Although macrophages were a major component of the cellular infiltrate in rejecting class I disparate grafts, they were also present in similar numbers in nonrejecting grafts . In addition, GIC harvested from nonrejecting grafts showed greater levels of in vitro cytotoxicity against target cells susceptible to NK cell-mediated lysis.
It is not possible, from these observations alone, to completely exclude a role for DTH in mediating rejection of class 1555 Gracie et al .
I disparate kidney grafts. However, there is convincing evidence, at least in the case of skin allografts, that the tissue destruction accompanying rejection is exquisitely specific (37, 38) , implying that either antigen-specific effector T cells or else alloantibody are responsible for graft rejection. In a vascularized allograft, the microvasculature is likely to be a critical target of the effector responses (39, 40) and the early vascular injury followed by ischemia and hemorrhage in the rejecting class I disparate renal allografts in the present experiments points to the vascular endothelium as being the major target ofthe rejection process . It is interesting to speculate that the requirements for an antigen-specific effector cell could be fulfilled by a class 11-restricted CD4+ T cell able to recognize allo-class I peptides, presented in the context of self class II MHC by donor endothelial cells. Although damage ofvascular endothelium by syngeneic antigenspecific CD4+ effector cells has a precedent in the rat model of experimental allergic encephalomyelitis (41), the suggestion that a CD4+ effector T cell is directly responsible for the rejection of class I disparate kidney grafts is made less likely by the observation that the vascular endothelium in these rejecting grafts remains largely class 11-negative (see Table 3 ).
The results of the present experiments are most consistent with the notion that CD4+ T cell-dependent alloantibody plays a decisive role in the rejection of RT1A' disparate kidney grafts by high responder RT1u recipients. Antibody could, in principal, mediate tissue damage through antibodydependent cellular cytotoxicity or by complement activation, resulting in endothelial activation and injury, release ofkinins and vasoactive peptides, and activation ofthe coagulation cascade. Indirect evidence that alloantibody may play a role in rejection was provided by the close correlation between the development of a strong RT1A' antibody response and graft rejection in RT1u recipients . The histopathological appearances of rejecting RT1A' kidneys were also consistent with antibody-mediated damage of the graft microvasculature since the endothelial injury occurred in the absence of significant infiltration of the vessel walls by mononuclear cells. Direct evidence that circulating anti-RTlA' antibody was capable of causing renal allograft damage in vivo was provided by the demonstration that passive transfer ofimmune serum was able to restore the ability of cyclosporin-treated RTlu recipients to reject RT1A' disparate but not third-party RTl°k idney grafts. Moreover, the histopathological appearance of these rejecting kidneys was similar to that seen in RTIA' disparate grafts undergoing rejection in unmodified RTlu recipients . The inability of passively transferred anti-RTlAimmune serum to cause rejection of RTIAa disparate kidney grafts in low responder RTl°rats is intriguing and may be attributed in part to the apparent differences in complement activity between the RTlu and RT1°rat strains.
The role ofalloantibody in acute rejection is controversial and it is generally accepted that cellular rather than humoral effector mechanisms are responsible for rejection of allogeneic grafts by unsensitized recipients . Adoptive transfer experiments in acutely irradiated rats have shown that purified T cells are able to restore rejection ofboth fully allogeneic (42, 
